15-48251703-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_000338.3(SLC12A1):c.1875G>A(p.Trp625Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000446 in 1,613,608 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.00032 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000016 ( 0 hom. )
Consequence
SLC12A1
NM_000338.3 stop_gained
NM_000338.3 stop_gained
Scores
5
1
1
Clinical Significance
Conservation
PhyloP100: 9.99
Genes affected
SLC12A1 (HGNC:10910): (solute carrier family 12 member 1) This gene encodes a kidney-specific sodium-potassium-chloride cotransporter that is expressed on the luminal membrane of renal epithelial cells of the thick ascending limb of Henle's loop and the macula densa. It plays a key role in concentrating urine and accounts for most of the NaCl resorption. It is sensitive to such diuretics as furosemide and bumetanide. Some Bartter-like syndromes result from defects in this gene. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional splice variants have been described but their biological validity in humans has not been experimentally proven.[provided by RefSeq, May 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 15-48251703-G-A is Pathogenic according to our data. Variant chr15-48251703-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 8754.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SLC12A1 | NM_000338.3 | c.1875G>A | p.Trp625Ter | stop_gained | 15/27 | ENST00000380993.8 | |
SLC12A1 | NM_001184832.2 | c.1875G>A | p.Trp625Ter | stop_gained | 15/27 | ||
SLC12A1 | NM_001384136.1 | c.1875G>A | p.Trp625Ter | stop_gained | 15/27 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SLC12A1 | ENST00000380993.8 | c.1875G>A | p.Trp625Ter | stop_gained | 15/27 | 5 | NM_000338.3 | A1 |
Frequencies
GnomAD3 genomes AF: 0.000315 AC: 48AN: 152152Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
48
AN:
152152
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000876 AC: 22AN: 251118Hom.: 0 AF XY: 0.0000884 AC XY: 12AN XY: 135706
GnomAD3 exomes
AF:
AC:
22
AN:
251118
Hom.:
AF XY:
AC XY:
12
AN XY:
135706
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1461456Hom.: 0 Cov.: 31 AF XY: 0.0000179 AC XY: 13AN XY: 727018
GnomAD4 exome
AF:
AC:
24
AN:
1461456
Hom.:
Cov.:
31
AF XY:
AC XY:
13
AN XY:
727018
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000315 AC: 48AN: 152152Hom.: 0 Cov.: 32 AF XY: 0.000457 AC XY: 34AN XY: 74332
GnomAD4 genome
AF:
AC:
48
AN:
152152
Hom.:
Cov.:
32
AF XY:
AC XY:
34
AN XY:
74332
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
SLC12A1-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 15, 2023 | The SLC12A1 c.1875G>A variant is predicted to result in premature protein termination (p.Trp625*). This variant was reported in the homozygous state in many Costa Rican patients with antenatal Bartter syndrome and is considered a founder variant in this population (Kurtz et al 1997. PubMed ID: 9355073).This variant is reported in 0.064% of alleles in individuals of Latino descent in gnomAD. Nonsense variants in SLC12A1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Bartter disease type 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 1997 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Oct 18, 2023 | This sequence change creates a premature translational stop signal (p.Trp625*) in the SLC12A1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC12A1 are known to be pathogenic (PMID: 8640224, 9585600, 19096086). This variant is present in population databases (rs137853159, gnomAD 0.06%). This premature translational stop signal has been observed in individual(s) with Bartter syndrome (PMID: 9355073). ClinVar contains an entry for this variant (Variation ID: 8754). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
A;A;A
Vest4
0.94, 0.94
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at